Ligand id: 8199

Name: sonidegib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 63.69
Molecular weight 485.19
XLogP 7.32
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
In July 2015, the US FDA approved sonidegib as a treatment for locally advanced basal cell carcinoma (recurring after surgery/radiation therapy or in patients for whom the latter are not an option). Phase II trials for cancers including multiple myeloma, platinum resistant recurrent ovarian cancer and ER/HER2 negative breast cancers, medulloblastoma and pancreatic cancer are ongoing. Click here to link to's full listing of sonidegib trials.